Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript Summary
Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript Summary
Cost reduction measures and financial transactions are expected to sustain the company's operations for approximately 18 months.The following is a summary of the Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript:
以下是2025年第二季度Beyond Air公司（XAIR）業績會議電話交易摘要：
Financial Performance:
財務表現:
Q2 FY 2025 reported revenue of $0.8 million, up from $0.2 million in the previous fiscal year's Q2.
The company anticipates gross margins to turn positive by March 2025.
Cost reduction measures and financial transactions are expected to sustain the company's operations for approximately 18 months.
2025財年第二季度報告的營業收入爲80萬美元，較上一個財政年度第二季度的20萬美元有所增長。
公司預計毛利率將在2025年3月前轉正。
預期成本降低措施和財務交易將維持公司運營約18個月。
Business Progress:
業務進展：
Beyond Air has increased its hospital clients by over 60% due to effective marketing and customer education.
Announced strategic partnerships aimed at expanding distribution, including agreements with Healthcare Links, TrillaMed, and BAC for market expansion outside the U.S.
Focus on regulatory approvals and product upgrades, with a PMA supplement for LungFit PH in cardiac surgery pending FDA review.
Planning to demonstrate next-generation LungFit PH system at upcoming AARC meeting.
由於有效營銷和客戶教育，Beyond Air的醫院客戶增加了60%以上。
宣佈旨在擴大分銷的戰略合作伙伴關係，包括與Healthcare Links、TrillaMed和BAC達成的協議，用於在美國以外市場擴張。
關注監管批准和產品升級，LungFit PH用於心臟手術的PMA補充正在等待FDA審查。
計劃在即將舉行的AARC會議上展示下一代LungFit PH系統。
Opportunities:
機會：
Expansion in international markets through partnerships and regulatory approvals.
Product line expansion with next-generation systems and broader label for current devices.
通過合作伙伴關係和監管批准在國際市場擴張。
通過下一代系統的產品線擴張和爲當前設備提供更廣泛標籤。
Risks:
風險：
The detailed financial and operational planning underscores potential risks tied to regulatory approvals and the successful negotiation of hospital contracts
詳細的財務和運營計劃凸顯了與監管批准和成功談判醫院合同相關的潛在風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
